{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:48:46Z","timestamp":1789811326476,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":2879,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1186\/s13613-018-0466-7","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T06:31:28Z","timestamp":1544423488000},"page":"122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients"],"prefix":"10.1016","volume":"8","author":[{"given":"Giorgio","family":"Berlot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Claudio","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Nieto Yabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Istrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Baronio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Quarantotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Bixio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Barbati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Dattola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Chillemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Scamperle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Iscra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariella","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s13613-018-0466-7_bb0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/viru.26516","article-title":"The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?","volume":"5","author":"Boomer","year":"2014","journal-title":"Virulence"},{"key":"10.1186\/s13613-018-0466-7_bb0015","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.2016.2691","article-title":"Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis","volume":"315","author":"van Vught","year":"2016","journal-title":"JAMA"},{"key":"10.1186\/s13613-018-0466-7_bb0020","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.intimp.2011.08.024","article-title":"Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients","volume":"11","author":"Venet","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1186\/s13613-018-0466-7_bb0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/SHK.0b013e3181a2c0b2","article-title":"Gamma-globulin levels in patients with community-acquired septic shock","volume":"32","author":"Taccone","year":"2009","journal-title":"Shock"},{"key":"10.1186\/s13613-018-0466-7_bb0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/01.shk.0000370606.30525.21","article-title":"Gamma-globulin levels in patients with community-acquired septic shock","volume":"33","author":"Myrianthefs","year":"2010","journal-title":"Shock"},{"key":"10.1186\/s13613-018-0466-7_bb0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1009899803032","article-title":"Structure and Function of Immunoglobulins","volume":"3","author":"Sp\u00e4th","year":"1999","journal-title":"Sepsis"},{"key":"10.1186\/s13613-018-0466-7_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1086\/421089","article-title":"Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review","volume":"39","author":"Pildal","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-018-0466-7_bb0045","first-page":"2686","article-title":"Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis","volume":"35","author":"Laupland","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-018-0466-7_bb0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7326\/0003-4819-146-3-200702060-00009","article-title":"Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis","volume":"146","author":"Turgeon","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1186\/s13613-018-0466-7_bb0055","first-page":"2677","article-title":"Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock","volume":"35","author":"Kreymann","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-018-0466-7_bb0060","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-018-0466-7_bb0065","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00134-018-5143-7","article-title":"Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)","volume":"44","author":"Welte","year":"2018","journal-title":"Intens Care Med"},{"key":"10.1186\/s13613-018-0466-7_bb0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13054-015-0793-0","article-title":"The original sins of clinical trials with intravenous immunoglobulins in sepsis","volume":"19","author":"Almansa","year":"2015","journal-title":"Crit Care"},{"key":"10.1186\/s13613-018-0466-7_bb0075","first-page":"102","article-title":"IgM-enriched Immunoglobulins in Sepsis","volume":"2009","author":"Esen","year":"2009"},{"key":"10.1186\/s13613-018-0466-7_bb0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2249.1998.00445.x","article-title":"Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product","volume":"111","author":"Trautmann","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1186\/s13613-018-0466-7_bb0085","first-page":"8","article-title":"Opsonic activity of a new intravenous immunoglobulin preparation: pentaglobin compared with Sandoglobulin","volume":"76","author":"Garbett","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"10.1186\/s13613-018-0466-7_bb0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1399-3089.2003.00098.x","article-title":"Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum","volume":"11","author":"Walpen","year":"2004","journal-title":"Xenotransplantation"},{"key":"10.1186\/s13613-018-0466-7_bb0095","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nri2849","article-title":"The importance of natural IgM: scavenger, protector and regulator","volume":"10","author":"Ehrenstein","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1186\/s13613-018-0466-7_bb0100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/cc10597","article-title":"Bench-to-bedside review: immunoglobulin therapy for sepsis\u2013biological plausibility from a critical care perspective","volume":"16","author":"Shankar-Hari","year":"2012","journal-title":"Crit Care"},{"key":"10.1186\/s13613-018-0466-7_bb0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s15010-014-0706-1","article-title":"In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens","volume":"43","author":"Rossmann","year":"2015","journal-title":"Infection"},{"key":"10.1186\/s13613-018-0466-7_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/shk.0b013e318067df15","article-title":"Effects of IgM-enriched solution on polymorphonuclear neutrophil function, bacterial clearance, and lung histology in endotoxemia","volume":"29","author":"Stehr","year":"2008","journal-title":"Shock"},{"key":"10.1186\/s13613-018-0466-7_bb0115","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.V93.3.942","article-title":"Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation","volume":"93","author":"Rieben","year":"1999","journal-title":"Blood"},{"key":"10.1186\/s13613-018-0466-7_bb0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcrc.2011.05.012","article-title":"Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis","volume":"27","author":"Berlot","year":"2012","journal-title":"J Crit Care"},{"key":"10.1186\/s13613-018-0466-7_bb0125","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The 3rd international consensus definitions for sepsis and septic shock","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1186\/s13613-018-0466-7_bb0130","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1186\/s13613-018-0466-7_bb0135","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CCM.0000000000002074","article-title":"Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome","volume":"45","author":"Mira","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-018-0466-7_bb0140","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/TA.0b013e318256e000","article-title":"Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care","volume":"72","author":"Gentile","year":"2012","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1186\/s13613-018-0466-7_bb0145","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(15)70112-X","article-title":"Sepsis: a roadmap for future research","volume":"15","author":"Cohen","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-018-0466-7_bb0150","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S2213-2600(16)00068-0","article-title":"Individual gene expression and personalised medicine in sepsis","volume":"4","author":"Vincent","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1186\/s13613-018-0466-7_bb0155","doi-asserted-by":"crossref","first-page":"R247","DOI":"10.1186\/cc13073","article-title":"Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome","volume":"17","author":"Giamarellos-Bourboulis","year":"2013","journal-title":"Crit Care"},{"key":"10.1186\/s13613-018-0466-7_bb0160","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ijantimicag.2015.10.013","article-title":"Endogenous immunoglobulins and sepsis: new perspectives for guiding replacement therapies","volume":"46","author":"Bermejo-Martin","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-018-0466-7_bb0165","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/joim.12265","article-title":"Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis","volume":"276","author":"Bermejo-Mart\u00edn","year":"2014","journal-title":"J Intern Med"},{"key":"10.1186\/s13613-018-0466-7_bb0170","unstructured":"Reinhart K, Brunkhorst FM, Bone HG, et al. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplin\u00e4re Vereinigung f\u00fcr Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci. 2010;8:Doc14."},{"key":"10.1186\/s13613-018-0466-7_bb0175","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1007\/s00134-014-3474-6","article-title":"Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock","volume":"40","author":"Cavazzuti","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-018-0466-7_bb0180","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-018-0466-7_bb0185","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","article-title":"Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program","volume":"42","author":"Ferrer","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-018-0466-7_bb0190","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/CCM.0000000000002264","article-title":"Delays From First Medical Contact to Antibiotic Administration for Sepsis","volume":"45","author":"Seymour","year":"2017","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1186\/s13613-018-0466-7_bb0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13613-017-0268-3","article-title":"The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure","volume":"7","author":"Martin-Loeches","year":"2017","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-018-0466-7_bb0200","doi-asserted-by":"crossref","unstructured":"Busani S, Serafini G, Mantovani E, et al. Mortality in patients with septic shock by multidrug resistant bacteria: risk factors and impact of sepsis treatments. J Intensive Care Med. 2017.","DOI":"10.1177\/0885066616688165"},{"key":"10.1186\/s13613-018-0466-7_bb0205","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cmi.2016.01.021","article-title":"Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins","volume":"22","author":"Giamarellos-Bourboulis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-018-0466-7_bb0210","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00134-015-3733-1","article-title":"Ten \u2018short-lived\u2019 beliefs in intensive care medicine","volume":"41","author":"Perner","year":"2015","journal-title":"Intensive Care Med"}],"updated-by":[{"DOI":"10.1186\/s13613-019-0504-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000}},{"DOI":"10.1186\/s13613-019-0504-0","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000}}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-018-0466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13613-018-0466-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025008891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025008891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-018-0466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:31:10Z","timestamp":1776670270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025008891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"alternative-id":["S2110582025008891"],"URL":"https:\/\/doi.org\/10.1186\/s13613-018-0466-7","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-018-0466-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The Author(s) 2018. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"122"}}